2023 Fiscal Year Research-status Report
Amelioration of temporomandibular joint osteoarthritis with Wwp2 message RNA therapy
| Project/Area Number |
23K16036
|
|---|
| Research Institution | Tokyo Medical and Dental University |
|---|
Principal Investigator |
周 君 東京医科歯科大学, 生体材料工学研究所, 特任助教 (40846507)
|
|---|
| Project Period (FY) |
2023-04-01 – 2026-03-31
|
| Keywords | Wwp2 / mRNA theraputics / Osteoarthritis |
|---|
| Outline of Annual Research Achievements |
Wwp2 mRNA was successfully established and treated in an in vitro chondrocyte-based osteoarthritis inflammation model using IL-1β induction. This model serves as a valuable tool for evaluating the therapeutic potential of Wwp2 mRNA in the context of OA-associated inflammation. Furthermore, we demonstrated that in vivo delivery of Wwp2 mRNA attenuates OA progression in an animal model, as evidenced by reduced cartilage damage.
|
| Current Status of Research Progress |
Current Status of Research Progress
2: Research has progressed on the whole more than it was originally planned.
Reason
We totally have 4 aims in this project during the grant applicaiton. In the first year, we completed all tasks related to Aim 1, evaluating the biological function of Wwp2 mRNA therapy in vitro, including the construction of Wwp2 mRNA and the establishment of an in vitro chondrocyte-based OA inflammation model. We also partially fulfilled Aim 2 by developing linear Wwp2 mRNA.
|
| Strategy for Future Research Activity |
In the next stages, we will focus on the remaining objectives: completing Aim 2 (Wwp2 circRNA development), Aim 3 (delivery of Wwp2 circRNA using polyplex nanomicelles), and Aim 4 (investigating TMJOA treatment outcomes and mechanisms using Wwp2 circRNA delivery in vivo).
|
| Causes of Carryover |
Due to taking a two-month maternity leave this fiscal year, the progress of experiments was affected, resulting in remaining unused fund. In the coming fiscal year, I plan to complete the unfinished parts of the research that were impacted by the leave.
|
